Clinical Trial Update: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients

View source ↗

Summary

This completed AstraZeneca-sponsored study (NCT06131424) investigated the prevalence of HER2-low status among patients with metastatic HER2-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: AstraZeneca | Conditions: HER2-negative | Status: COMPLETED